Psilocin & Psilocybin

Psilocin is a naturally occurring psychedelic that has been used for hundreds of years. It is found alongside psilocybin in a number of fungal species, particularly of the Psilocybe genus. Psilocybin is a prodrug for psilocin.

It has a very low physical harm potential, though psychological concerns do exist. Acute issues like psychosis and panic attacks have been recorded. Lasting psychological problems are rare.

Psilocin = Psilocybin; Shrooms; Magic Mushrooms; Teonanacatl

Dose

Oral (mushrooms)

Light: .25 – 1 g

Common: 1 – 3 g

Strong: 3 – 5+ g

Timeline

Oral

Total: 4 – 7 hours

Onset: 00:20 – 01:00

Experience Reports

Erowid

References

(2012) A fatal case of ‘magic mushroom’ ingestion in a heart transplant recipient.

(2012) Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin

(2011) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

(2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

(2011) Harm potential of magic mushroom use: a review.

(2011) Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness

(2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

(2007) Effects of psilocybin on time perception and temporal control of behaviour in humans.

(2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

(2006) Response of cluster headache to psilocybin and LSD.

(2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.

(2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.

(2003) Morphological and chemical analysis of magic mushrooms in Japan.

(2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.

(2002) The pharmacology of psilocybin.

(1999) Tragic flying attempt under the influence of “magic mushrooms”

(1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man–a PET study with [11C]raclopride.

(1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.

(1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.

(1996) The psilometric scale of comparative potency of selected Psilocybe mushrooms

(1996) Fatal Poisoning After a Group of People Voluntarily Consumed Hallucinogenic Mushrooms

(1996) Magic mushrooms: hope for a ‘cheap high’ resulting in end-stage renal failure.

(1994) Extraction and analysis of indole derivatives from fungal biomass.

(1962) Comparison of psilocin with psilocybin, mescaline and LSD-25.